SCHEMBL2652440

SCHEMBL2652440

CCOC(=O)CCNC(=O)c1ccc(C=O)o1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
LTA4H P09960 4/20 0.44
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
HSP90AA1 P07900 1/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP4Z1 Q86W10 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22289272 0.82 HPGD (0.49) HPGDTSHRKDM4ENPC1RAB9A
SCHEMBL2662991 0.80 L3MBTL1 (0.63) HPGDTSHRMAPTNPC1RAB9A
SCHEMBL3494577 0.79 KMT2A (0.49) HPGDTSHRKDM4ENPC1RAB9A
SCHEMBL8580330 0.78 LMNA (0.47) HPGDTSHRMAPTKDM4ENPC1
SCHEMBL13402898 0.77 ALDH1A1 (0.49) HPGDTSHRMAPTNPC1RAB9A
SCHEMBL3496498 0.77 KMT2A (0.54) HPGDTSHRKDM4ENPC1RAB9A
SCHEMBL13402902 0.76 POLB (0.45) HPGDTSHRKDM4ENPC1RAB9A
SCHEMBL2926770 0.75 MAPT (0.60) HPGDTSHRMAPTKDM4ENPC1
SCHEMBL13402915 0.75 CYP2D6 (0.48) HPGDTSHRKDM4ELMNATP53
SCHEMBL2650710 0.75 MAPT (0.54) HPGDMAPTKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR HPGD 1678/4885TSHR 95/4885LTA4H 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.